CURRENT REPORT 5/2025
February 25, 2025

Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline

The Management Board of Ryvu Therapeutics S.A., with its registered office in Kraków, Poland (the "**Issuer**", the "**Company**", "**Ryvu**") hereby informs about the decisions to undertake strategic reorganization measures aimed at extending the Company's cash runway from Q1 to H2 2026, to focus on driving the RVU120 clinical program and the early pipeline to key data inflection points.

As part of the strategic reorganization mentioned above, the Company has taken actions primarily in two areas:

1. Workforce reduction
2. Pipeline adjustments

Re 1. Workforce reduction

The Management Board of the Company informs about the completion of the consultation procedure with the representatives of the Company's employees on the intention to carry out a collective redundancy in the Company (the "**Collective Redundancy**") and about the adoption of the rules of the Collective Redundancy specifying the rules of conduct in matters concerning the employees affected by the intended Collective Redundancy and about the decision of the Management Board of the Company to carry out the Collective Redundancy on the terms set out in the established rules. The Collective Redundancy will be carried out as of February 25, 2025 to June 30, 2025 and will affect approximately 30% (no more than 95) employees of the Company. As a result of Collective Redundancy, the Company will still employ approximately 200 employees, retaining its full potential to develop the projects described below.

Re 2. Pipeline adjustments

The Management Board has decided on changes to the project pipeline. Current status and key project objectives in the period 2025-2026:

In case of RIVER-52 – a Phase II clinical trial of RVU120 as a monotherapy in patients with r/r AML or HR-MDS – initiated as in the Current Report No. 10/2024 dated February 14, 2024, the Management Board of Ryvu decided to suspend the enrollment of new patients

to focus investment on the other RVU120 development paths. Currently enrolled patients will continue to receive treatment per protocol. Other RVU120 Phase II studies (RIVER-81, POTAMI-61 and REMARK) progress as planned. The decision to progress RIVER-81 and suspend enrollment in RIVER-52 was based on data analysis and feedback from advisory boards in February 2025. The next data update for RVU120 is planned in Q2 2025.

In the RVU305 program, which the Company announced in Current Report No. 28/2024 dated September 10, 2024, IND/CTA-enabling studies are ongoing. Their completion is planned for H2 2025.

For preclinical discovery and research, the Company will pursue a dual-pronged strategy, each of which has the potential to generate multiple oncology medicines:

(i) **ONCO Prime – novel small molecule precision medicine**: as part of its proprietary ONCO Prime platform, Ryvu will continue to advance several novel precision oncology targets, including synthetic lethality targets.

(ii) **ADCs (antibody-drug conjugates) with novel payloads**: Ryvu will continue to develop ADCs with next-generation novel payloads, including synthetically lethal and immunomodulatory mechanisms. Ryvu will work on novel ADCs internally and through the existing collaboration with Exelixis (STING-based ADCs). The WRN program, which previously was focused on standalone development, will be developed as a novel ADC payload program to differentiate on efficacy, resistance profile and safety versus competitors.

Ryvu continues to advance three key biopharma partnerships (BioNTech, Exelixis and Menarini), unchanged from its previous status, retaining full reimbursement for its expenses and the potential to earn financial milestones.

Cash runway and cash position

As a result of workforce reductions and pipeline adjustments, the Company's cash runway has been extended from Q1 to H2 2026. As of February 23, 2025 Ryvu held approximately €46 million (PLN 192 million) in cash and other financial assets. In addition, the Company has secured approximately €22 million (PLN 91 million) in non-dilutive grant funding. According to the Management Board's assessment, these funds will support the achievement of the objectives outlined in this report, including the execution of the RVU120 clinical program and the advancement of early-stage projects to key data inflection points.

Investor Webinar

Due to the strategic reorganization, Ryvu Management Board will host an investor meeting, February 25, at 10:15 am CET.

The webinar can be accessed at the following link: https://ryvu.clickmeeting.com/investor-meeting

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 17.4 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice-President of the Management Board